How would you treat a fit, newly diagnosed, high-risk multiple myeloma patient with multiple poor risk factors and circulating plasma cells?  

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a more intensive induction therapy? And consolidation with an allogenic transplant?



Answer from: Medical Oncologist at Community Practice